Finance

Beta
Lists
ALPEKA:BMV
Alpek SAB de CV
MX$12.19
-0.49%
(-0.060) 1D
Jun 4, 2:00:00 PM GMT-6  ·   MXN
All symbols
SymbolPriceChange% Change
Generating top insights for ALPEKA...
Open
MX$12.18
High
MX$12.25
Low
MX$12.02
Mkt. cap
25.56B
Avg. vol.
4.20M
Volume
1.76M
52-wk high
MX$13.00
52-wk low
MX$8.07
EPS
-MX$1.92
Shares outstanding
2.11B
No. of employees
5K
Open
MX$12.18
High
MX$12.25
Low
MX$12.02
Mkt. cap
25.56B
Avg. vol.
4.20M
Volume
1.76M
52-wk high
MX$13.00
52-wk low
MX$8.07
EPS
-MX$1.92
Shares outstanding
2.11B
No. of employees
5K
Analyst outlook
Analyst Ratings
Based on 2 analysts giving stock ratings to ALPEKA in the past 3 months
Buy
Buy
1
Hold
1
Sell
0
12 month forecast
Based on 2 Wall Street analysts offering 12 month price targets for ALPEKA in the last 3 months.
Highest
Current €12.19
€0.56 (-95.39%)
Average
€0.56 (-95.41%)
Lowest
€0.56 (-95.39%)
News stories
From sources across the web
Profile
Alpek S.A.B. de C.V., known as Alpek, is a Mexican chemical manufacturing company headquartered in San Pedro Garza García, in Nuevo León, Mexico. It is one of the largest PET and PTA producers in the Americas and the sole producer of polypropylene and caprolactam in Mexico. It is the largest business unit of the industrial conglomerate Alfa, representing 37% of its revenues for 2014. It is also the largest chemical company in Mexico according to Expansion magazine. Alpek reported revenues of $6.5 billion for 2014. It operates facilities in 21 sites in the United States, Mexico, Brazil, Argentina and Chile and employs 5,000 people. Alpek was listed on the Mexican Stock Exchange on April 26, 2012, and is a constituent of the IPC, the main benchmark index of the Mexican Stock Exchange. Wikipedia
About Alpek SAB de CV
CEOJose de Jesus Valdez Simancas
Employees5.21K
Founded1975
Headquarters-
SectorCommodity chemical
Websitealpek.com
Previous reportsAll values in MXN
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in MXN
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
32.79B
31.07B
27.96B
29.76B
Cost of goods sold
30.83B
28.77B
26.90B
26.77B
Cost of revenue
30.83B
28.77B
26.90B
26.77B
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
1.41B
1.31B
1.41B
1.32B
Operating expense
1.35B
2.13B
1.23B
1.36B
Total operating expenses
32.18B
30.90B
28.13B
28.14B
Operating income
606.54M
175.50M
-170.79M
1.62B
Other non operating income
-188.89M
-306.02M
-174.02M
-282.59M
EBT including unusual items
504.34M
-528.82M
-781.51M
-730.83M
EBT excluding unusual items
504.34M
-528.82M
-888.66M
951.22M
Income tax expense
1.03B
143.99M
646.34M
184.90M
Effective tax rate
203.40%
-27.23%
-82.70%
-25.30%
Other operating expenses
-61.44M
813.89M
-183.82M
46.33M
Net income
-571.99M
-807.34M
-1.56B
-1.12B
Net profit margin
-1.74%
-2.60%
-5.60%
-3.76%
Earnings per share
-0.27
-0.19
-0.70
-
Interest and investment income
67.71M
67.06M
56.36M
32.55M
Interest expense
-555.43M
-595.00M
-583.54M
-519.48M
Net interest expenses
-487.72M
-527.94M
-527.18M
-486.93M
Depreciation and amortization charges
-
-
-
-
EBITDA
1.91B
1.45B
788.71M
2.86B
Gain or loss from assets sale
7.13M
4.97M
-91.77M
-1.62M
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer